Cosmo Feilding Mellen is a drug development entrepreneur dedicated to unlocking the medical potential of psychoactive substances. In 2019, he co-founded Beckley Psytech, a private, clinical-stage biotechnology company on a mission to develop novel, rapid-acting, short-duration psychedelic medicines that address the huge unmet need of those living with neuropsychiatric conditions around the world.

Prior to that, he worked closely with with the Beckley Foundation – a world-leading non-profit NGO focused on evidence-based drug policy reform and scientific research into psychedelic medicines – for over 15 years and, in 2016, he co-founded Beckley Research and Innovations to develop ethical business models focused on scientific research into medical cannabis and psychedelics. Cosmo subsequently served as Co-Founder and Managing Director of Beckley Canopy Therapeutics, a cannabis-based drug development company, and Spectrum Biomedical UK, a medical cannabis distribution company. In 2019, both of these companies were acquired by Canopy Growth Corporation.